Prevention and management of preterm labour

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 22, Issue SUPPL.2, 2009, Pages 24-30

  Petraglia, Felice ^a   Visser, Gerard H A ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ATOSIBAN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; CALCIUM ANTAGONIST; CLINDAMYCIN; CORTICOSTEROID; DEXAMETHASONE; FIBRONECTIN; GLYCERYL TRINITRATE; ISOSORBIDE; MAGNESIUM SULFATE; NIFEDIPINE; NITRIC OXIDE DONOR; PROSTAGLANDIN SYNTHASE INHIBITOR; RITODRINE; SALBUTAMOL; TERBUTALINE; UTERUS SPASMOLYTIC AGENT;

ATTENTION DEFICIT DISORDER; CEREBRAL PALSY; CERVICAL LENGTH MEASUREMENT; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECONOMIC ASPECT; FEMALE GENITAL TRACT INFECTION; GASTROINTESTINAL HEMORRHAGE; GESTATIONAL AGE; GROUP B STREPTOCOCCAL INFECTION; HEART FAILURE; HIGH RISK PREGNANCY; HUMAN; HYPOTENSION; HYPOXIA; INFANT MORTALITY; LUNG DISEASE; LUNG DYSPLASIA; LUNG EDEMA; MATERNAL MORBIDITY; MATERNAL MORTALITY; MENTAL DEFICIENCY; NECROTIZING ENTEROCOLITIS; NERVOUS SYSTEM DEVELOPMENT; NEWBORN DEATH; NEWBORN DISEASE; NEWBORN MORBIDITY; NEWBORN MORTALITY; PREMATURE LABOR; PRENATAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RETROLENTAL FIBROPLASIA; REVIEW; RISK REDUCTION; SENSORY DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL; TRANSVAGINAL ECHOGRAPHY; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; FEMALE; FETAL ORGAN MATURITY; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MORBIDITY; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREMATURE BIRTH; TOCOLYTIC AGENTS;

EID: 70350647414     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050902860708     Document Type: Review

References (46)

1. Iams JD, Romero R, Culhane JF, Goldenberg RL. Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet 2008; 371:164-175.
2. Di Renzo GC, Roura LC; European Association of Perinatal Medicine-Study Group on Preterm Birth. Guidelines for the management of spontaneous preterm labor. J Perinat Med 2006;34:359-366.
3. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2008;371: 261-269.
4. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006:CD004454.
5. Lee BH, Stoll BJ, McDonald SA, Higgins RD; National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcomes of extremely low birthweight infants exposed prenatally to dexamethasone versus betamethasone. Pediatrics 2008;121:289-296.
6. Lee BH, Stoll BJ, McDonald SA, Higgins RD; National Institute of Child Health and Human Development Neonatal Research Network. Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. Pediatrics 2006;117:1503-1510.
7. Spinillo A, Viazzo F, Colleoni R, Chiara A, Maria Cerbo R, Fazzi E. Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol 2004;191:217-224.
8. Rogowski J. Measuring the cost of neonatal and perinatal care. Pediatrics 1999;103:329-335.
9. Jones JS, Istwan NB, Jacques D, Coleman SK, Stanziano G. Is 34 weeks an acceptable goal for a complicated singleton pregnancy? Managed Care 2002;11:42-47.
10. Petrou S, Henderson J, Bracewell M, Hockley C, Wolke D, Marlow N; EPICure Study Group. Pushing the boundaries of viability: the economic impact of extreme preterm birth. Early Hum Dev 2006;82:77-84.
11. Kiefer DG, Vintzileos AM. The utility of fetal fibronectin in the prediction and prevention of spontaneous preterm birth. Rev Obstet Gynecol 2008;1:106-112.
12. Crane JM, Van den Hof MC, Armson BA, Liston R. Transvaginal ultrasound in the prediction of preterm delivery: singleton and twin pregnancies. Obstet Gynecol 1997;90:357-363.
13. To MS, Skentou C, Cicero S, Nicolaides KH. Cervical assessment at the routine 23 weeks' scan: problems with transabdominal sonography. Ultrasound Obstet Gynecol 2000;15:292-296.
14. Fonseca EB, Cellik E, Parra M, Singh M, Nicolaides K. Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007;357:462-469.
15. Royal College of Obstetricians and Gynaecologists. Tocolytic drugs for women in preterm labour. Clinical Guidelines No.1 (B) Oct 2002.
16. Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille JC, Tabor B, Perry KG, Varner M, Goodwin TM, Lane R, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000;182:1173-1183.
17. Atosiban. Summary of Product Characteristics. Ferring Pharmaceuticals Ltd. Jan 2000.
18. Moutquin JM, Sherman D, Cohen H, Mohide PT, Hochner- Celnikier D, Fejgin M, Liston RM, Dansereau J, Mazor M, Shalev E, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obstet Gynecol 2000;182:1191-1199.
19. European Atosiban Study Group. The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study. Acta Obstet Gynecol Scand 2001;80:413-422.
20. Worldwide Atosiban versus Beta-agonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group. BJOG 2001;108:133-142.
21. Kam KY, Lamont RF. Developments in the pharmacotherapeutic management of spontaneous preterm labor. Expert Opin Pharmacother 2008;9:1153-1168.
22. Giles W, Bisits A. Preterm labour. The present and future of tocolysis. Best Pract Res Clin Obstet Gynaecol 2007;21:857-868.
23. Grimes DA, Nanda K. Magnesium sulfate tocolysis: time to quit. Obstet Gynecol 2006;108:986-989.
24. Thornton JG. Maintenance tocolysis. BJOG 2005;112:118-121.
25. Helmer H. Frequently asked questions on tocolytics. BJOG 2005;112:94-96.
26. Crowther CA, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Database Syst Rev 2007:CD003935.
27. Guinn DA, Atkinson MW, Sullivan L, Lee M, MacGregor S, Parilla BV, Davies J, Hanlon-Lundberg K, Simpson L, Stone J, et al. Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: A randomized controlled trial. JAMA 2001;286:1581-1587.
28. Crowther CA, Haslam RR, Hiller JE, Doyle LW, Robinson JS; Australasian Collaborative Trial of Repeat Doses of Steroids (ACTORDS) Study Group. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet 2006;367:1913- 1919.
29. Wapner RJ, Sorokin Y, Thom EA, Johnson F, Dudley DJ, Spong CY, Peaceman AM, Leveno KJ, Harper M, Caritis SN, et al. National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network. Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. Am J Obstet Gynecol 2006;195:633-642.
30. Wapner RJ, Sorokin Y, Mele L, Johnson F, Dudley DJ, Spong CY, Peaceman AM, Leveno KJ, Malone F, Caritis SN, et al. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Long-term outcomes after repeat doses of antenatal corticosteroids. N Engl J Med 2007;357:1190-1198.
31. Murphy KE, Hannah ME, Willan AR, Hewson SA, Ohlsson A, Kelly EN, Matthews SG, Saigal S, Asztalos E, Ross S, et al. MACS Collaborative Group. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. Lancet 2008;372:2143-2151.
32. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (596 hours) corticosteroids for preventing chronic lung disease in preterminfants. Cochrane Database Syst Rev 2003:CD001146.
33. Noorlander CW, Visser GH, Ramakers GM, Nikkels PG, de Graan PN. Prenatal corticosteroid exposure affects hippocampal plasticity and reduces lifespan. Dev Neurobiol 2008; 68:237-246.
34. Newnham JP, Jobe AH. Should we be prescribing repeated courses of antenatal corticosteroids. Semin Fetal Neonatal Med 2008, Dec 5 (Epub ahead of print).
35. Wijnberger LDE, Nikkels PGJ, van Bel F, Visser GHA. Effects of antenatal glucocorticoid therapy on hippocampal histology of preterm infants. In: LDE Wiinberger PhD. Diagnosis and treatment of fetal lung immaturity. University of Utrecht; 2002. pp 47-62.
36. Mulder EJH, de Heus R, Visser GHA. Antenatal corticosteroid therapy: short-term effects on fetal behaviour and haemodynamics. Semin Fetal Neonatal Med 2008, Dec 5 (Epub ahead of print).
37. de Heus R, Mol BW, Erwich JJ, van Geijn HP, Gyselaers WJ, Hanssens M, Harmark L, van Holsbeke CD, Duvekot JJ, Schobben F, et al. Adverse drug reactions to tocolytic treatment for preterm labour. BMJ 2009;338:b744.
38. Carey JC, Klebanoff MA, Hauth JC, Hillier SL, Thom EA, Ernest JM, Heine RP, Nugent RP, Fischer ML, Leveno KJ, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000;342: 534-540.
39. Kenyon SL, Taylor DJ, Tarnow-Mordi W; ORACLE Collaborative Group. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group. Lancet 2001;357:989-994. (Pubitemid 32285390)
40. Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, Taylor DJ. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet 2008;372:1319-1327.
41. Lamont RF, Duncan SL, Mandal D, Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 2003;101:516-522.
42. Seo K, McGregor JA, French JI. Preterm birth is associated with increased risk of maternal and neonatal infection. Obstet Gynecol 1992;79:75-80.
43. Rosenstein IJ, Morgan DJ, Lamont RF, Sheehan M, Doré CJ, Hay PE, Taylor-Robinson D. Effect of intravaginal clindamycin cream on pregnancy outcome and on abnormal vaginal microbial flora of pregnant women. Infect Dis Obstet Gynecol 2000;8:158-165.
44. Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ 2004;329:371.
45. Larsson PG, Fa°hraeus L, Carlsson B, Jakobsson T, Forsum U; Premature study group of the Southeast Health Care Region of Sweden. Late miscarriage and preterm birth after treatment with clindamycin: a randomised consent design study according to Zelen. BJOG 2006;113:629-637. (Pubitemid 43781693)
46. Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003;361:983-988.